Abstract
Objectives: The severe coronavirus disease 2019 (COVID-19) is characterized by acute respiratory distress syndrome (ARDS) and risk of fungal co-infection, pulmonary aspergillosis in particular. However, COVID-19 associated pulmonary aspergillosis (CAPA) cases remain limited due to the difficulty in diagnosis.
Methods: We describe presumptive invasive aspergillosis in eight patients diagnosed with COVID-19 in a single center in Shenzhen, China. Data collected include underlying conditions, mycological findings, immunodetection results, therapies and outcomes.
Results: Four of the eight patients had tested positive for Aspergillus by either culture or Next-generation sequencing analysis of sputum or bronchoalveolar lavage fluid (BALF), while the rest of patients had only positive results in antigen or antibody detection. Although all patients received antifungal therapies, six of these eight patients (66.7%) died.
Conclusion: Due to the high mortality rate of CAPA, clinical care in patients with CAPA deserves more attention.
Keywords: Anti-Aspergillus IgG; COVID-19; Galactomannan; Pulmonary aspergillosis.
【저자키워드】 COVID-19, galactomannan, Pulmonary aspergillosis., Anti-Aspergillus IgG, 【초록키워드】 ARDS, therapy, Diagnosis, risk, sputum, Antigen, China, outcomes, Antibody detection, Bronchoalveolar lavage fluid, Culture, Patient, Co-infection, clinical care, Aspergillus, underlying conditions, BALF, fungal, Therapies, acute respiratory distress, pulmonary aspergillosis, Shenzhen, severe coronavirus disease, positive result, syndrome, single center, high mortality rate, positive, Sequencing analysis, invasive, tested, collected, died, include, eight, characterized, diagnosed with COVID-19, 【제목키워드】 Care, Shenzhen, city,